ACIP recommends additional updated COVID-19 vaccine dose for adults 65 and older

The Advisory Committee on Immunization Practices (ACIP) has issued a recommendation regarding COVID-19 vaccination for older adults. The recommendation states that all people ages 65 years and older should receive one additional dose of any updated (2023-2024 Formula) COVID-19 vaccine. This recommendation applies to the United States population.

The specific evidence base supporting this recommendation was not reported in the provided information. Key details including the study type, study phase, sample size, comparator groups, primary and secondary outcomes, and follow-up duration were not specified. No numerical results on vaccine effectiveness, efficacy, or comparative performance were provided.

Safety and tolerability information was also not reported, including data on adverse events, serious adverse events, or discontinuation rates. The limitations of the underlying evidence were not detailed. The funding sources and potential conflicts of interest for the committee or the evidence reviewed were not reported.

This represents a formal public health practice recommendation from a national advisory body. Clinicians should be aware of this updated guidance for their older adult patients. The recommendation should be interpreted in the context of the full ACIP statement and current CDC guidelines, as the specific data driving the decision is not presented here.